Clinical trials: Pheochromocytoma/Paraganglioma
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated…
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
- Trial name
- NCT04924075
- Testing
- Belzutifan
- Where
- 84 sites in United States, Australia and 20 more
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
Pheochromocytoma, Paraganglioma
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Background: Pheochromocytoma and paraganglioma are rare tumors. They usually form inside and near the adrenal gland or in the neck region.
- Conditions
- Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors, Neuroendocrine Neoplasms
- Trial name
- NCT03206060
- Testing
- Lu-177-DOTATATE, Ga-68-DOTATATE
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Carcinomas, Neuroendocrine Tumors
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Background: Neuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal glands, and other areas of the body.
- Conditions
- Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Carcinoma, Adrenocortical
- Trial name
- NCT06041516
- Testing
- ADCT-701
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
Background: Gastrointestinal neuroendocrine tumors (GI NET) are a type of cancer that affects the stomach and intestines; pheochromocytoma/paragangliomas (PPGL) are tumors that grow in or near the adrenal glands.
- Conditions
- Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Paragangliomas
- Trial name
- NCT06427798
- Testing
- 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
- Conditions
- Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor
- Trial name
- NCT05636618
- Testing
- [203Pb]VMT-α-NET, [212Pb]VMT-α-NET
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- Perspective Therapeutics
Pheochromocytoma, Paraganglioma
211At-MABG in Adults With Advanced Neuroendocrine Cancers
Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible…
- Conditions
- Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors, Medullary Thyroid Cancer
- Trial name
- NCT07661420
- Testing
- 1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pennsylvania
Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal…
- Conditions
- Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma
- Trial name
- NCT06479811
- Testing
- [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma
A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin…
- Conditions
- Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma, SSTR-expressing Tumors, Medullary Thyroid Carcinoma
- Trial name
- NET-COMPARE (NCT07621146)
- Testing
- 68Ga-DOTATATE PET/CT, 18F-AmBF3-TATE PET/CT
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Advanced Pheochromocytoma and Paraganglioma, PCPG
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).
- Trial name
- NCT07282587
- Testing
- ONC206, ONC206: Dose 1, ONC206: Dose 2
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Jazz Pharmaceuticals
Risk Grading System, Pheochromocytoma and Paraganglioma (PPGL)
The IUPU-PPGL Score: A Imaging-Based Tool for Stratifying Surgical Complexity in Patients With Pheochromocytoma and Paragangliom（PPGL）
This study aimed to develop the imaging-based IUPU-PPGL score and evaluate its ability to stratify surgical complexity and its association with perioperative outcomes.
- Conditions
- Risk Grading System, Pheochromocytoma and Paraganglioma (PPGL), Quantitative Assessment
- Trial name
- NCT07412158
- Testing
- observational diagnostic model development
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University First Hospital
Adrenocortical Carcinoma, Pheochromocytoma
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ACC or PPGL.
- Conditions
- Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT07743138
- Testing
- Ivonescimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first…
- Conditions
- Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma
- Trial name
- NCT04394858
- Testing
- Biospecimen Collection, Computed Tomography with Contrast, Magnetic Resonance Imaging
- Where
- 163 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Genetic Predisposition, Paraganglioma
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic…
- Conditions
- Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS
- Trial name
- NCT06377033
- Testing
- Behavioral nudge
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Pheochromocytoma, Paraganglioma
Zanzalintinib in Unresectable and Progressive MPGGs
This study is to examine the effects of oral daily zanzalintinib in participants with unresectable, progressive metastatic pheochromocytoma or paraganglioma.
- Trial name
- NCT07714551
- Testing
- Zanzalintinib
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma
- Trial name
- NCT02721732
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- M.D. Anderson Cancer Center
Pheochromocytomas, Paragangliomas
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)
This multicenter retrospective Italian study evaluates the efficacy and safety of PRRT in patients with advanced, unresectable or metastatic pheochromocytomas and paragangliomas (PPGL).
- Trial name
- PRRT-PGL-PHEO (NCT07538791)
- Testing
- Peptide Receptor Radionuclide Therapy (PRRT)
- Where
- 10 sites in Italy
- Volunteers
- 210 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Pheochromocytoma, Paraganglioma
Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
Pheochromocytomas and paragangliomas (PPGL) are rare tumors treated by surgical excision. During follow-up, more than 15% of patients will have recurrences in the form of new tumors, locoregional recurrence or metastases.
- Trial name
- e-PPGL (NCT04573816)
- Testing
- Use of an internet plateform
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant
An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'.
- Conditions
- Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant, Pheochromocytoma, Metastatic, Pheochromocytoma/Paraganglioma
- Trial name
- NCT07680205
- Testing
- Belzutifan
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Acute Leukemia, Adenomatous Polyposis
Familial Investigations of Childhood Cancer Predisposition
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll.
- Conditions
- Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML
- Trial name
- SJFAMILY (NCT03050268)
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- St. Jude Children's Research Hospital